Evidence map›Paper›PMID 40183747›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2025

A Microfluidic Blood Brain Barrier Model to Study the Influence of Glioblastoma Tumor Cells on BBB Function.

Thomas DePalma, Marco Rodriguez, Luke Kollin, Kennedy Hughes, Katie Jones, Emerie Stagner, Monica Venere, Aleksander Skardal

Abstract read
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Thomas DePalmaDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, 43210, USA.
Marco RodriguezDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, 43210, USA.
Luke KollinDepartment of Radiation Oncology, Ohio State University, Columbus, OH, 43210, USA.
Kennedy HughesDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, 43210, USA.
Katie JonesDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, 43210, USA.
Emerie StagnerDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, 43210, USA.
Monica VenereDepartment of Radiation Oncology, Ohio State University, Columbus, OH, 43210, USA.
Aleksander SkardalDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, 43210, USA.ORCID 0000-0002-2138-2453

Funding

Role of FACT in ZFTA-RelA fusion driven ependymomaR01CA280203 · NCI · OHIO STATE UNIVERSITY · PI Stephen C Mack, Monica Venere · 2023 to 2026
$2.8M
Predicting Tumor Heterogeneity Evolution After Therapy In Patient-Derived Ex Vivo Glioblastoma OrganoidsR21CA229027 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SKARDAL, ALEKSANDER, STROWD, ROY ERVIN · 2018 to 2019
$597k
Investigating KIF20A as a therapeutic target in glioblastomaR21CA271217 · NCI · OHIO STATE UNIVERSITY · PI SUMMERS, MATTHEW K, VENERE, MONICA · 2024 to 2024
$405k
Medical Technology Enterprise Consortium W81XWH-15-9-0001NCI NIH HHS R01CA280203NCI NIH HHS R21 CA229027NCI NIH HHS R21CA229027NCI NIH HHS R21CA271217Pelotonia n/a
6 · The paper itself

Abstract

The blood brain barrier (BBB) plays an essential role in regulating brain function by controlling the transport of nutrients and preventing toxins from moving from the rest of the body's circulation into the brain. Because it is more selective than most other endothelial barriers, many therapeutic candidates fail to cross the BBB, making it difficult to design novel drugs to treat many pathologies in the brain. In addition, BBB dysfunction is observed in many brain diseases including glioblastoma (GB), an aggressive, universally fatal primary brain tumor. Here, a novel 3D microfluidic model of the BBB is designed using human cells and a brain-mimetic hydrogel. The in vitro BBB model replicates several key functions of the human BBB. This system has low permeability to small molecules and responds to inflammatory cues. The addition of GB cells to the model reveals that BBB function changes in a tumor-cell-population-dependent manner. Some GB cell populations lead to increased diffusive permeability while others induce increased immune cell binding. Together, these results indicate that this model can be used to investigate disease progression and drug delivery in GB.

Indexed as

Blood-Brain BarrierBrain NeoplasmsGlioblastomaMicrofluidicsModels, BiologicalCell Line, TumorHumansLab-On-A-Chip DevicesPermeabilityblood brain barrierglioblastomamicrophysiological systemsorgan‐on‐a‐chip

Identifiers

PMID40183747
PMCPMC12989235

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.